Toshiaki Tanaka

Toshiaki Tanaka

Auto-generated profile, based on publicly available information

Toshiaki Tanaka

Department of Life Science and Technology Institute of Science Tokyo Yokohama‐shi Kanagawa Japan

Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

14 November 2007 in Journal of Cellular Biochemistry
Verified
Journal Article
Closed access
PDF file
ESErika Shirako
Erika Shirako
NHNaoki Hirayama
Naoki Hirayama
YTYu‐Ichi Tsukada
Yu‐Ichi Tsukada
TTToshiaki Tanaka
Toshiaki Tanaka
NKNaomi Kitamura
Naomi Kitamura

1 July 2009 in Molecular Cancer Research
Verified
Journal Article
Open access
PDF file
KUKazutaka Ushio
Kazutaka Ushio
THTomio Hashimoto
Tomio Hashimoto
NKNaomi Kitamura
Naomi Kitamura
TTToshiaki Tanaka
Toshiaki Tanaka
Hepatocyte growth factor (HGF) inhibits the proliferation of several tumor cell lines and tumor growth in vivo. We showed previously that HGF induces cell cycle arrest at G1 in a human hepatoma cell line, HepG2, by up-regulating the expression of p16INK4a through strong activation of extracellular signal-regulated kinase (ERK). However, although essential, the activation was not sufficient for the up-regulation of p16. In this study, we examined regulatory mechanisms of p16 expression through a transcription factor, Ets, which has been shown previously to bind to the promoter. The treatment of HepG2 cells with HGF induced ERK-dependent phosphorylation of Ets, which leads to its activation, before the up-regulation of p16, suggesting that another factor suppresses Ets activity. We found that HGF reduces the amount of Id1, which is a dominant-negative inhibitor of Ets, leading to a decrease in Ets associated with Id1. Id1 was down-regulated via transcriptional regulation not via the ubiquitin-proteasome-mediated pathway. Inhibition of the HGF-induced high-intensity ERK activity had a modest effect on the Id1 down-regulation, and inhibition of the phosphatidylinositol 3-kinase pathway had no effect, showing that Id1 is regulated by ERK-dependent and -independent pathways other than the phosphatidylinositol 3-kinase pathway. Exogenously expressed Id1 suppressed the up-regulation of p16 by HGF and the antiproliferative effect of HGF. Knockdown of Id1 significantly enhanced the activity of the p16 promoter coordinately with the activation of ERK. Our results indicated that down-regulation of Id1 plays a key role in the inhibitory effect of HGF on cell proliferation and provides a molecular basis for cancer therapy with HGF. (Mol Cancer Res 2009;7(7):1179–88)

1 March 2012 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
KMKaoru Miyokawa-Gorin
Kaoru Miyokawa-Gorin
KTKazuto Takahashi
Kazuto Takahashi
KHKeiko Handa
Keiko Handa
AKAtsuko Kitahara
Atsuko Kitahara
YSYoshikazu Sumitani
Yoshikazu Sumitani
HIHitoshi Ishida
Hitoshi Ishida

1 November 2013 in Molecular Cancer Research
Verified
Journal Article
Open access
PDF file
XLXiaoran Li
Xiaoran Li
YBYing Bian
Ying Bian
YTYuri Takizawa
Yuri Takizawa
THTomio Hashimoto
Tomio Hashimoto
TIToshiyuki Ikoma
Toshiyuki Ikoma
TTToshiaki Tanaka
Toshiaki Tanaka
Hepatocyte growth factor (HGF) has an inhibitory effect on human HepG2 hepatoma cell proliferation. Previously, it was shown that HGF treatment downregulated Id1 and upregulated p16INK4a in an ERK-dependent manner, leading to the inhibition of cellular proliferation. Here, new insight suggests that Skp2, an SCF complex component and potential prognosticator in cancer, is downregulated by injection of HGF into established HepG2 xenograft tumors. The downregulation was evident at both the mRNA and protein level and in an ERK-dependent manner. Critically, high expression of Skp2 restored HGF-inhibited cell proliferation, indicating that the inhibitory effect of HGF required the downregulation of Skp2. However, downregulation was not involved in the HGF-induced upregulation of a CDK inhibitor, p27Kip1, a known SCF-Skp2 target. Instead, data revealed that Skp2 regulated Myc activity, which has oncogenic potential in the generation of hepatocellular carcinoma. Elevated expression of Skp2 or a mutant that is unable to associate with the SCF complex was capable of activating Myc, suggesting that Skp2 does not act on Myc as a component of the SCF complex, and thus functions as an activator of Myc independent of its role in ubiquitination. Furthermore, Skp2 regulated Id1 expression by regulating Myc activity, and the regulation of Skp2 is involved in the activity of p16 promoter through regulation of Id1 expression. Overall, these mechanistic findings provide the first evidence that ERK-dependent downregulation of Skp2 reduced Myc activity, leading to HGF-induced inhibition of cell proliferation through decreased Id1 expression. Implications: This study elucidates the molecular details of HGF-induced inhibition of cellular proliferation in liver cancer cells. Mol Cancer Res; 11(11); 1437–47. ©2013 AACR.

1 September 1994 in Bulletin of the Chemical Society of Japan
Verified
Journal Article
Closed access
YKYoshikata Koga
Yoshikata Koga
TTToshiaki Tanaka
Toshiaki Tanaka
TATooru Atake
Tooru Atake
PWPeter Westh
Peter Westh
AHAase Hvidt
Aase Hvidt
Liquid–solid phase diagram was determined in the water-rich region of aqueous 2-butoxyethanol. A solid addition compound was suggested with the composition = 0.0260, which melts incongruently at 269.5 K. The mixing scheme boundary separating two regions in the single liquid phase domain (Chem. Phys. Lett., 217, 245 (1994)) was found to cross the incongruent melting point of the above solid addition compound.